Form 144 Filer Information SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK0001537529Filer CCCXXXXXXXIs this a LIVE or TEST Filing?Is LIVE TESTSubmission Contact InformationIs this a Live of the second secon

Name Phone E-Mail Address

144: Issuer Information

Name of Issuer	IONIS PHARMACEUTICALS INC
SEC File Number	000-19125
Address of Issuer	2855 GAZELLE COURT CARLSBAD CALIFORNIA 92010
Phone	7609319200
Name of Person for Whose Account the Securities are To Be Sold	Monia Brett P
See the definition of "nerver" in performed (a) of Dule 144 Inform	ation is to be given not only as to the newsor

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer Relationship to Issuer Officer Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker		Aggregate Market Value			Name the Securities Exchange
COMMON STOCK	INSIGHT SECURITIES, INC. 600 CENTRAL STE 293 HIGHLAND PARK IL 60030	18650	787952.50	143100000	07/07/2023	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON STOCK	01/15/2012 (COMPENSATION	IONIS PHARMACEUTICALS, INC.			643	01/15/2012	COMPENSATION
COMMON STOCK	01/15/2017 (IONIS PHARMACEUTICALS, INC.			5036	01/15/2017	COMPENSATION
COMON STOCK	01/15/2018 (COMPENSATION	IONIS PHARMACEUTICALS, INC.			5389	01/15/2018	COMPENSATION
COMMON STOCK	01/15/2019 (COMPENSATION	IONIS PHARMACEUTICALS, INC.			7582	01/15/2019	COMPENSATION

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Brett P. Molina 2855 GAZELLE COURT CARLSBAD CA 92010	COMMON STOCK	05/22/2023	7117	197907.16

144: Remarks and Signature

Remarks	INSIGHT SECURITIES SOLD 18,650 SHARES OF IONIS PHARMACUETICALS, INC. FOR BRETT MONIA.
Date of Notice	07/07/2023
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	01/30/2023

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION:

MICHAEL MAKULA

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)